GLP-1 agonists in type 2 diabetes: 20% fewer composite kidney events, with cardiovascular and survival benefit

Design

Systematic review and random-effects meta-analysis of RCTs

Population

20 trials, 83,004 people with type 2 diabetes

Primary outcome

MACE, death and composite renal outcome vs placebo

Effect

Renal composite RR 0.80 (0.73 to 0.88); MACE 0.87; all-cause death 0.89

A systematic review and meta-analysis in European Heart Journal – Quality of Care and Clinical Outcomes (September 2026) pooled 20 placebo-controlled randomised trials of GLP-1 receptor agonists in 83,004 people with type 2 diabetes, searched to March 2025.

GLP-1 agonists reduced the composite kidney outcome (RR 0.80, 95% CI 0.73 to 0.88), major adverse cardiovascular events (0.87, 0.83 to 0.92), all-cause death (0.89, 0.84 to 0.93), cardiovascular death (0.88), myocardial infarction (0.87) and stroke (0.88). Heart failure admission (0.93, 0.85 to 1.01) and coronary revascularisation were not significantly reduced.

Composite kidney outcomes varied between trials and may include albuminuria progression, which is softer than kidney failure. The analysis pools different agents and populations.

For the nephrologist, the practical point is that GLP-1 agonists belong alongside RAS blockade and SGLT2 inhibitors in diabetic kidney disease, not only as glucose or weight drugs.

• Consider a GLP-1 agonist for patients with type 2 diabetes and CKD, alongside RAS blockade and an SGLT2 inhibitor
• Check the urine albumin-creatinine ratio before and during treatment to track kidney response
• Use agents with kidney and cardiovascular outcome data where available
• Counsel about gastrointestinal effects and dose-titrate slowly in advanced CKD
• Do not rely on a GLP-1 agonist to reduce heart failure admissions — that effect was not significant

Why it matters

It places GLP-1 agonists firmly among kidney-protective therapies in diabetes rather than as glucose-lowering alone.

Don't overread it

Kidney composites varied between trials and may include albuminuria progression, which is softer than kidney failure.

The statistics, in plain English

A risk ratio of 0.80 means 20% fewer composite kidney events; the interval (0.73 to 0.88) is narrow and well below 1. The heart failure estimate (0.93, 0.85 to 1.01) crosses 1, so it may reflect no effect.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.